Company intelligence / Profile preview

MAHA Therapeutics

Newton, MA, USA

Ownership: Private
Development stage: Other

Overview

Maha Therapeutics is a biotechnology company focused on the development of small molecule inhibitors targeting MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1). Founded by Dr. Vikas Sukhatme and Dr. Vidula Sukhatme, the company aims to translate research on the MALT1 protease into novel therapies for hematological malignancies and solid tumors. MALT1 is a critical component of the CBM complex that mediates NF-κB signaling, and its inhibition is particularly relevant for the activated B-cell (ABC) subtype of diffuse large B-cell lymphoma. Additionally, the company explores MALT1 inhibition as a strategy to modulate regulatory T cells (Tregs) within the tumor microenvironment to enhance anti-tumor immune responses.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on MAHA Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAHA Therapeutics.

Explore the full profile